


























































































































































































































































































































In# the# last#decade,# there#has#been#an# increased#awareness#about# the#diagnosis#and#
treatment#of#psychiatric#disorders#in#childhood.#As#a#consequence,#there#has#been#a#
concomitant#increase#in#the#prescription#of#psychiatric#medication#(psychotropics)#for#




South# Africa,# and# needs# to# be# enhanced.# It# is# crucial# to# understand# the# current#
patterns#of#prescribing#in#order#to#assess,#plan,#and#improve#children’s#mental#health#
care# services.# It# is# also# useful# to# compare#the# data# from# Tara# Hospital# Outpatient#





the# period# between# January# 2010# and#December# 2011.# A# review# of# the# literature#










# To#describe# the#current#prescribing#patterns#of#medical#practitioners#at#TOCC# for#
new#patients#between#the#ages#of#6#and#14#years#old.##
The#objectives#of#the#study#are:##
• To# examine# the# overall# use# of# psychiatric#medication# in# recently# referred#
children#presenting#at#the#clinic.#
• To# evaluate# the# demographic# and# clinical# diagnoses# associated# with# the#
prescribed#medication.#






! There# is# a# general# paucity# of# knowledge# with# regards# to# the# prescription# of#
psychiatric# medication# in# children# in# South# Africa.# Specifically# at# TOCC,# the#
psychopharmacological# practices# of# the# child# psychiatrists# and# psychiatric#
registrars# are# unknown.# This# information# is# crucial# in# order# to# monitor# current#
patterns#and#prevent#potential#harmful#prescribing#of#psychotropics.#
1.5!!!!Structure!of!report:!
In# the# following# chapter,# the# report# looks# at# existing# international# and# local#










children,# outpatient,# community,# office,# office# based,# clinic,# psychotropic,#
psychostimulant,#antidepressant#(selective#serotonin#reuptake#inhibitors#(SSRI)#and#














psychostimulants,# antidepressants# and# atypical# antipsychotics.# Very# few# drugs# are#
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impulsivity.10# In# order# for# these# symptoms# to# be# diagnostically# relevant,# they# should#
develop# before# the# age# of# 7# years# and#must# be# developmentally# inappropriate# and#
impair#the#child’s#social#and#academic#functioning.10##
ADHD# has# a# multi>factorial# aetiology,# including# environmental,# genetic# and#
neurobiological# factors.5# Neurobiological# factors# include# catecholaminergic#
dysregulation#in#cortical#areas,#specifically#the#pre>frontal#cortex#(PFC)#and#the#cortico>
striatal>thalamic>cortical# circuits# (CSTC).11# These# cortical# regions# are# responsible# for#
modulating# attention,# motor# activity# and# impulsivity.# Psychostimulants# increase# the#
concentration#of#catecholamines#in#these#regions,#improving#cortical#functioning.11#
Psychostimulants#should#be#part#of#a#comprehensive#treatment#plan#for#ADHD#which#
includes# psychological,# behavioural# and# social# interventions.4# Registered#medications#
for# use# in# children# with# ADHD# in# South# Africa# are# psychostimulants# which# include#
various# versions# of# Methylphenidate.12# Methylphenidate# (a# psychostimulant),# binds#
and# inhibits# the# function# of# the# norepinephrine# transporter# receptor# and# dopamine#
transporter# receptor# on# neurons# in# the# PFC# and# CSTC.11# This# results# in# decreased#
catecholamine# reuptake,# increasing# the# concentration# of# these# neurotransmitters# in#






for# the# treatment# of# ADHD.12# It# works# in# a# similar# way,# but# selectively# acts# on# the#
norepinephrine# re>uptake# inhibitor# and# is# classified# as# a# selective# norepinephrine#
reuptake#inhibitor.11,12##
The#South#African#Society#of#Psychiatrists#(SASOP)#recently#published#guidelines#for#the#
treatment# of# ADHD.13# They# advise# a# full# psychiatric# evaluation# and# appropriate#
assessment# prior# to# commencing# treatment# and# provide# guidelines# for# acute# non>
pharmacological#and#pharmacological#treatment.13#Should#pharmacological#treatment#
be# indicated,# they# advise# to# start# with# a# low# dose# of# methylphenidate# (5>10mg#
Immediate# Release)# in# the# morning.13# The# dose# should# then# be# titrated# upwards# if#
needed#and#split#during#the#day.#Similarly,#the#National#Institute#of#Health#and#Clinical#
Excellence# (NICE)# guidelines# recommend#Methylphenidate# as# a# first# line#medication,#
but#add#that#atomoxetine#is#an#accepted#first#line#alternate.8#Third#line#medications#for#
treatment# of# ADHD# according# to# the#Maudsley# Prescribing# Guidelines# and# the# NICE#
guidelines,#include#clonidine#and#TCAs.4,#8#
# Psychostimulants# are# the# most# common# psychotropics# prescribed# in# the# paediatric#
population.14#A#recent#study#from#McCabe#et#al,#looked#at#a#large#multi>cohort#of#high#
school# seniors# (modal#age#18)# in# the#United#States#of#America# (USA),#and# found#that#
the# lifetime#prevalence#of#medical#use#of#prescription# stimulant#was#9.5%.14#Clark#et#
al15# looked# at# prescribing# practices# in# British# children,# and# found# that# 46%(n=845)#
received# psychostimulants# for# hyperkinetic# disorders# (International# Classification# of#
Disease# 10th# edition# equivalent# of# ADHD).16# Similarly,# a# New# York# outpatient# study5#
showed#that#35%#of#956#children#prescribed#psychotropics,#received#psychostimulants.#





Service# at# Rahima# Moosa# Mother# and# Child# Hospital# (RMH)# in# Coronationville,#
Johannesburg.# The# study# investigated# clinical# and# demographic# features# of# children#
attending# this# clinic# and# revealed# that# 38%# of# the# children# that# were# prescribed#
medication,#received#psychostimulants.17#
# Psychostimulant# prescriptions# are# on# the# rise,# with# an#increased# prevalence# of#
prescriptions# in# the# USA,# UK# and# the# Netherlands.1# Hodgkins# et# al18# found# in# a#
Netherlands#based# study,# that# the#prevalence#of#psychostimulants#prescriptions# rose#
from#110#per#10,000#in#2000#to#210#per#10,000#in#2007.##Studies#in#the#United#Kingdom#
established# similar# findings,# with# a# doubling# of# the# rate# of# Methylphenidate#
prescriptions#between#2003#and#2008.19#Reasons#postulated#for#this#trend# include#an#
increased# awareness# of# ADHD# by# parents# and# educators# and# improved# knowledge#
about#the#appropriate#use#of#psychostimulants.19#There#is#a#dearth#of#studies#about#the#
prevalence#of#prescriptions#of#psychostimulants#in#South#Africa.#
Concerns# with# psychostimulant# use,# not# covered# in# this# report,# include# the# growing#
abuse#of#prescription#stimulants#for#non>medical#reasons.#McCabe’s#research#showed#






! More# males# than# females#have#ADHD,# and# accordingly# more# males# receive#





psychostimulant# prescriptions# of# 4:1.20# Furthermore,# a# retrospective# study# in# the#
Netherlands# showed# that#males#made#up#82%# (n=4030)#of# a#group#of#4,909#children#
initiated#on#ADHD#treatment.18#Multiple#international#studies#support#these#findings.1,#






the# UK# showed# that# the# six# to# twelve# year# old# group# received# the# majority# of#
psychostimulants.15# Locally,# Truter21# found# that# seven# to# twelve# year# olds# made# up#
63.14#%#of#patients#receiving#psychostimulants#(n=1028).##
! Race:! !
Data# is# inconsistent# and# scant# with# respect# to# investigating# racial# variances# in#
psychostimulant# prescribing.# Some# earlier# American# studies# indicate# increased#
psychostimulant# prescription# in# non>African# American# children# compared# to# their#
African# American# counterparts.5# More# recent# studies# have# shown# a# narrowing# of#
differences# in# prescribing# patterns# between# different# racial# groups.22# Zito# et# al#
reviewed# data# that# looked# at# racial# differences# and# concluded# that# racial# bias# or#
confounding#factors#such#as#medical#insurance#type#may#affect#results.22#There#are#no#
data#on#racial#differences#in#South#African#prescribing#patterns#
# Psychostimulants#are# the#most# commonly#prescribed#psychotropics# in# children.#Male#







# Significant# differences# in# the# prescribing# patterns# of# antidepressants# have# been#
observed#with#reference#to#patient#clinical#and#demographic#features.#Antidepressants#
have# antidepressant,# anxiolytic# and# impulse>reducing# properties.11# Furthermore#
antidepressants# are# also# used# in# the# treatment# of# enuresis.23# Selective# serotonin#




enuretic# disorders.23>26# Mood# and# anxiety# disorders# have# complex# aetiologies.# They#
occur# because# of# a# multi>faceted# interaction# between# environmental# and#
neurobiological#factors.11! It# is#postulated#that#the#underlying#biological#factors#for#the#
development#of#mood#and#anxiety#disorders,#are#the#deficiencies#and/or#dysregulation#




# The#only#antidepressants# registered# for#use# in#South#Africa#are#Clomipramine# (a#TCA#
for#treatment#of#obsessive#compulsive#disorder)#in#over#5#year#olds,#and#Imipramine#(a#
TCA#for#treatment#of#nocturnal#enuresis)#in#5#to#8#year#olds.12#According#to#the#South#
African#Medicines# Formulary# (SAMF)# 11th# edition,# Fluoxetine# (SSRI)# can# be# used# off>






treatment# of# obsessive# compulsive# disorder.12# The# NICE# guidelines,# recommend#
fluoxetine# as# a# first# line# medication# of# choice# in# depression# in# combination# with#
psychological# treatment.25# Citalopram# (SSRI)# and# escitalopram(SSRI)# are# also#
recommended#by#NICE#for#treatment#of#depressive#disorders.#Additionally#NICE#advise#
against# the#use#of# TCAs# for# depression,# due# to# their# higher# propensity# to# cause# side#
effects.25#
# Antidepressants#are#used#for#a#range#of#anxiety#disorders#including#(as#per#DSM>IVTR),#
generalised# anxiety# disorder,# post>traumatic# stress# disorder,# obsessive# compulsive#
disorder# and# social# or# specific# phobias.10,24# Anxiety# disorders# in# children# tend# to#
respond# well# to# Cognitive# Behavioural# Therapy# (CBT),# but# if# the# anxiety# disorder# is#
severe# or# if# CBT# has# failed/or# is# not# indicated,# then# medication# is# prescribed.4,24#
Furthermore,#first#line#pharmacological#treatment#of#anxiety#disorders#are#SSRI’s.4,24#
Tricyclic# antidepressants# block# serotonin# and# norepinephrine# reuptake# transporters,#
thus# increasing# the# concentration# of# these# neurotransmitters# resulting# in# the#
alleviation#of#mood#and#anxiety#symptoms.11However#a#meta>analysis,#carried#out#by#




# Selective# serotonin# reuptake# inhibitors#have# relatively# few#side#effects#and# therefore#






are# the# first# line#antidepressants# for# the# treatment#of#mood#and#anxiety#disorders# in#
children.#SSRI’s#have#a#complicated#mechanism#of#action#and#inhibit#the#reuptake#of#5>
hydroxytryptamine# (5HT,# serotonin),# resulting# in# an# increase# of# 5HT# at# the# neural#
synapses.11##
# The#use#of#SSRI’s# increased#dramatically#since#the# late#1990’s;#that# is#until#the#widely#
publicised#Black#Box#warning# in#2004#by#the#FDA#resulted#in#a#worldwide#decrease# in#
SSRI#prescriptions.28,#29,30#The#concern#was#that#on#initiating#SSRI’s,#there#was#an#initial#
increase# in# suicidal# ideation.29#More# recent# studies,# have# clarified# and# refuted# these#
claims,# and# have# found# that# the# benefits# of# SSRI# use# outweigh# any# potential# side#
effects.#
Various# countries# have# different# prescription# patterns.# Studies# in# the# UK,# USA# and#
Canada,# showed# that# SSRI’s# are# more# likely# to# be# prescribed# than# TCAs.15,20,28# In#
contrast,# Germany# and# France# show# higher# prescription# rates# of# tricyclic#














professional.26# Tricyclic# antidepressants# are# also# used# in# the# treatment# of# ADHD,#
however#only#after#failure#to#respond#to#two#or#more#stimulants#and#Atomoxetine.8#!
2.2.2! Demographic! characteristics! associated! with! antidepressant!!
prescription:!
# As# stated# above,# antidepressants# are# mainly# used# in# the# treatment# of# depressive,#
anxiety#and#enuretic#disorders.#There#are#differences#in#the#demographics#in#terms#of#
the# presentation# of# these# disorders,# which# reflects# in# antidepressant# prescription#
trends.3,#33##
!!!!!!!!Gender:!!
# Antidepressant# prescription# differs# between# the# sexes.3,20# In# the#majority# of# studies,#
females# under# the# age# of# 18# receive# more# prescriptions# for# antidepressants#
(specifically# SSRIS)# than# their#male# counterparts.1,29# This# is# because# of# the# increased#
prevalence#of#mood#and#anxiety#disorders#in#females.25#Females#over#the#age#of#13#are#
twice# # as# likely# to# develop# a# unipolar# depression# compared# to# males.28,36# In#
prepubescent# children#however,# there# is# an#equivocal# number#of#males# and# females#
that#develop#depression.25#Locally,#Burger#et#al#confirmed#the#findings#of#the#majority#
of# international# studies# that# showed# that# more# females# under# the# age# of# 18# year##




Antidepressant# prescriptions# increase# with# age.25,38,39# The# age# differences# in#





Kessler# et# al# # in# the#National# Survey# # in# 2005,# looked# at# the#median# age#of# onset# of#
psychiatric# disorders# in# the# United# States# of# America# (USA).40# They# found# that# the#
median#age#of#onset# for# anxiety#disorders#was#11# years# and#mood#disorders#was#25#
year.40# Locally# the# South# African# Stress# and# Health# (SASH)# study# reported# that# the#
median#age#of#anxiety#and#mood#disorders#was#32#years#and#37#years#respectively.36#




of# antidepressants# in#over#15# year#olds#was# at# a# ratio#of# female# to#male#of# 3:1,# and#
were# mainly# SSRI’s.# # Moreover,# he# showed# that# in# the# under>twelve# year’s# group,#
males#received#more#antidepressants#(specifically#TCAs)#than#females#with#a#5:3#ratio#
of#male#to#female.38##
# Locally,# Burger# et# al34# confirmed# the#majority# of# international# findings,# showing# that#
more#females#receive#prescriptions#for#antidepressants#than#males.#Additionally,#they#
showed#that#under#nine#year#olds#were#more#likely#to#receive#tricyclic#antidepressants,#
and# older# age# groups# were# more# likely# to# be# prescribed# SSRI’s.# 34# These# findings#
correlate#with#Murrays#finding#from#the#UK.38#
! Race:#
# Racial# disparities# were# most# significant# the# prescription# patterns# in# the#
antidepressant# group# of# psychotropics.# .41# A# large# USA# study# by# Stevens# et# al42#
looking# at# Medical# Aid# data,# showed# convincingly# that# Black# youths# were#





Hispanic# (NH)#White# youths.# Other# studies# on# children# and# adults# made# similar#








Typical# and# atypical# antipsychotics# treat# psychotic# and# non>psychotic# conditions# in#
children.# Psychotic# disorders# include# schizophrenia,# organic# psychosis# and# substance#
induced# psychotic# disorder.45# They# are# also# used# to# treat# psychosis# associated# with#
mood# disorders.45# Non>psychotic# disorders# include# bipolar# Disorder# 1# without#














Atypical# antipsychotics,# used# in# paediatric# patients,# are# serotonin>dopamine#
antagonists.#They#include#olanzapine;#quetiapine,#aripiprazole#and#risperidone.11#These#
atypical# antipsychotics# exert# their# action# through# their# antagonistic# effects# on#
dopamine_1# receptor# (D1),# dopamine_2# receptor# (D2)# and# 5HT# receptors.# They# exert#
multiple# effects# and# are# used# to# treat# psychosis,# mood# instability# and# problematic#
behaviour.# Major# concerns# with# atypical# antipsychotics# are# adverse# effects# of#
hyperprolactinemia,#weight#gain,#and#metabolic#syndrome.11#Data#are#scarce#regarding#
the#long>term#safety#and#adverse#effects#of#these#agents#on#the#developing#brain.#
# Doey# et# al# looked# at# atypical# antipsychotic# prescriptions# in# children# and# reasons# for#
their#prescription.47They#found#that#a#considerable#percentage#of#physicians#prescribe#
the#medications#for#symptoms#and#for#diagnoses#that#have#not#been#previously#studied#
for# efficacy# and# safety.# The#most# common# indication# for# the# prescription#was# ‘poor#
frustration#tolerance’#(75%)#followed#by#‘impulsivity’#(65%).#47##
# #Atypical# Antipsychotics# are# first# line# pharmacological# treatment# for# irritability,#
aggression#and#self>injurious#behaviour#in#children#with#autism#spectrum#disorder#and#
conduct#disorder.4,#48,49#The#NICE#guidelines#caution#that#antipsychotics#should#only#be#
used# once# other# psychosocial# interventions# aimed# at# reducing# disruptive# behaviour#
have#not#worked#or#are#not#possible.48,49# In#South#Africa,# risperidone# is# registered#for#
the# treatment#of# conduct#and#behavioural#disorders# in# children# (5>12#years#old)#with#
sub>average# intelligence# or# mental# retardation.12# # Holford# et# al50# looked# at# mild# to#
moderately##intellectually#disabled#paediatric#outpatients##with#behavioural#disorders.50##
This#local#multicentre#study#showed#that#34#children#with#behavioural#disorders#largely#
responded#well# to#a#slowly# titrated,# low#dose#of#oral# risperidone# (mean#dose#1.47mg#





gain,# raised#prolactin# levels#and#sleepiness)# that#peaked#at# three#months#and#did#not#
evolve#further#during#the#yearlong#trial.50##
In# the# last# fifteen# years# there# has# been# an# increase# in# paediatric# antipsychotic#
prescribing.16,22,51! An# FDA# advisory# committee# looking# at# the# use# of# atypical#
antipsychotics# in# children# showed# that# from# 2004,# there# was# a# 22%# increase# in#
prescriptions#of# these#medications.51# This# has#been#attributed# to# the# increase# in#off>
label# prescriptions.51# Of# controversy# in# the# literature# currently# is# the# increasing# off>
label#use#of#antipsychotics#as#behavioural#modifiers#in#foster#care#children.52,53##
Burcu#et#al53# recently#published#a# large# study# looking#at#atypical#antipsychotic#use# in#
children# on#Medicaid# Insurance# in# the#USA.# Children# in# foster# care# had# the# greatest#
duration#of#atypical#antipsychotic#exposure.#Additionally#one#in#three#children#in#foster#
care# with# a# diagnosis# of# ADHD# alone# were# treated# with# atypical# antipsychotics#
presumably#for#troublesome#behaviour.53#The#benefits#of#treating#disruptive#behaviour#
in#children#in#foster#care#with#atypical#antipsychotics#needs#to#be#carefully#weighed#up#
against# the# risk#of#harmful# side#effects# (e.g.#metabolic# syndrome#and#weight#gain)#of#
the#medication.51,54##
Atypical# antipsychotics# are# also# used# in# the# treatment# of# child# and# adolescent# onset#
bipolar#disorder#and#schizophrenia.55,# 56# FDA#approved#agents# for# treatment#of#acute#
mania# or# mixed# episodes# include# risperidone,# olanzapine,# quetiapine# and#
aripiprazole.57>60#Recent#research#has#shown#that#atypical#antipsychotics#may#be#more#
efficacious# than# traditional#mood# stabilizers# (anticonvulsants# and# lithium)# in# treating#
bipolar# disorder.55,# 61# The# main# concern# with# using# these# agents# in# children# as#





labelling# cautions# with# regard# to# the# increased# potential# for# weight# gain# and#
hyperlipidemia#in#children#and#adolescents#compared#to#adults.54,#57,60###
There# is# limited#research# in#South#Africa#on#atypical#antipsychotic#use,#but# looking#at#
Raman’s#aforementioned#study#in#Johannesburg#at#RMH,#she#found#that#almost#15%#of#





# There# is# a# preponderance# of# males# in# all# age# groups# receiving# prescriptions# of#
antipsychotics# compared# to# their# female# counterparts.1,62# # Males# present# more#
frequently# with# tic# disorders,# disruptive# disorders# and# pervasive# developmental#
disorders.# Studies# in#Canada,#UK,#USA,#Denmark#and#Netherlands#all# support# the#
finding#of#a#male#preponderance#for#the#prescription#of##antipsychotics.63>66##
! Age:!!
# Consistently# across# all# studies,# adolescents# receive# more# prescriptions# for#




adolescence#and#early# adulthood#due# to# the#onset#of#psychotic#disorders#during# this#








be# due# to# the# sample# populations# from# which# the# data# is# derived.# # Olfson# et# al66#
showed# that# when# confounding# factors# such# as# medical# insurance# and# number# of#
health# care# visits# were# taken# into# account,# they# showed# that# there# were# few#
differences# in# prescriptions# according# to# race.# Sleath# et# al# found# no# differences# in# a#
smaller#outpatient#New#York#study,#whereas#other# larger#studies#showed#an#African–
American#predominance#of#antipsychotic#prescription.44#
# In# summary,# the# use# of# atypical# antipsychotics# in# children# is# increasing# and# remains#
controversial.# Atypical# antipsychotics# are# used# for# licensed# indications,# and# are#
commonly#used#off>label#to#treat#aggression,#hyperactivity#and#irritability.#Older#male#




# Pharmaco>epidemiological# information# on# other# psychotropics# including# mood#
stabilizers# (anticonvulsants# and# lithium)# and# alpha>antagonists# (clonidine)# have# been#
explored#in#the#literature,#and#as#a#group#they#make#up#a#relative#minority#of#the#total#
prescriptions#in#children#and#adolescents.##
# The# NICE# guidelines# indicate# that#mood# stabilisers# (anticonvulsants# and# lithium)# are#
used#in#the#treatment#and#prophylaxis#of#Bipolar#disorder#in#children.55#They#are#used#





episodes.# NICE# guidelines# indicate# that# the# pharmacological# treatment# of# Bipolar#
disorder#in#children#and#adolescents#is#similar#to#adults.55#
# Lithium,#valproate#and#carbamazepine#have#been#shown#to#treat#acute#manic#phases#in#
children.# There# are# fewer# trials# investigating# acute# bipolar# depressive# episodes,# but#
there# is# some# evidence# of# a# response# to# lithium# and# lamotrigine# (either# as#
monotherapy# or# augmentation).# It# is# advised# that# psychological# treatment# aimed# at#
treating# a# depressive# episode# should# also# be# considered# when# treating# a# bipolar#
depressive#episode#in#under#18#year#olds.55##








to# promote# the# use# of# these# agents# together# as# well# as# reports# of# adverse# drug#
events.69#Concomitant#medication#is#either#used#to#treat#two#comorbid#conditions#with#
different#medications,# or# is# used# to# augment# existing# treatment# to#which# there#may#
have#been#an#inadequate#response.69#Factors#increasing#concomitant#psychotropic#use#













disorder# in# addition# to# a# primary# ADHD# diagnosis.# Recently# Betts# et# al71# looked# at#
prescribing#data#for#over#100,000##children#between#6#and#17#years#of#age#receiving#a#
stimulant# for# a# primary# ADHD# diagnosis).# # The# most# common# combination# of#
medication#was# a# stimulant# and# an# SSRI# (17.6%),# followed#by# atypical# antipsychotics#




psychotropic# prescribing# in# the# USA# in# 2005# revealed# that# approximately# 20%# of#
children#on#psychotropics# received# two#or#more#medications.72# Since# the#prevalence#
rate# of# antipsychotic# prescriptions# (commonly# used# as# augmentation# agents)# is#
increasing# it# is# suspected# that#the# current# figures#are#higher.# Comer’s# recent# USA#
study70# showed# a# concerning# rate# of# 32%# concomitant# prescriptions.# Prevalence#
studies# in# Iceland# and# Turkey# have# shown#around# an# 18%# rate# of# polypharmacy.73,74#
There# are# no# South# African# studies# looking# at# paediatric# concomitant# psychotropic#
prescribing.#
2.6!!!!!OffWlabel!prescribing!of!psychotropics:!






# Off>label# prescribing# is# common# in# children# and# does# not# imply# contra>indicated#
prescribing.75#These#prescriptions#are#based#on#the#extrapolation#of#efficacy#and#side#
effect#profiles#in#adults.#In#child#psychiatry#off>label#use#includes#use#of#a#medication#in#
an# unregistered# age# group# for# a# registered# condition# or#unregistered#use# of# a#
medication# for#a#condition#or# symptoms,#as# indicated# in#Table#2.2.##Areas#of#concern#
with# off>label# use# are# the# safety,# efficacy# and# the# use# of# these# medications# in# the#
absence#of#strong#evidence.2#
# Off>label#use# is#common#in#children#for#the#following#reasons.#Firstly#most#drug#trials#
are# developed# for# adults,# with# efficacy# in# children# needing# to# be# extrapolated.2,3#
Because#of# this# there# is#a# relative# lack#of#psychotropics# registered# for#children#which#
limits# clinician’s# options.# It# is# suggested# that# off>label# prescribing# occurs# based# on#















Class,#Subclass# Drug# Indication# Target#symptoms#
Antidepressants#


































on#and#off># label#antidepressant#prescribing# in#6>18#year#olds.3#He# found#nine#out#of#
ten# antidepressant# prescriptions# were# for# off>label# indications.# The#most# commonly#












Our# study# aims# to# describe# the# demographic# and# clinical# variables# associated# with#




















# The# study# is# a# retrospective# file# review.# Data# was# collected# from# all# new# patients#
attending# the# TOCC# from# 1st# January# 2010# to# the# end# of# December# 2011.# Further#
analysis#of# the#records# followed#to#determine#the#sample.#The#data# from#the#sample#
was#then#captured#onto#data#collection#sheets.##
3.2!!!Study!setting:!
# The# Child# Outpatient# Clinic# is# at# the# Tara# H# Moross# Psychiatric# Hospital# (Tara),#
Hurlingham,#Johannesburg,#South#Africa.#Tara# is#a#state#hospital#providing#specialised#
psychiatric# services# and# also# forms# part# of# the# University# of# the# Witwatersrand#
























3)## Children# already# on# psychiatric# medication.# These# children# were# excluded# since# the#





































# Children#may# have#more# than# one# Axis# I# diagnosis,# and# each# unique# diagnosis# was#




















































Descriptive# analyses# of# all# variables# occurred,# and# data# were# grouped# according# to#
categories#in#order#to#make#statistical#calculations#more#meaningful:##
• Age:# The# age# of# the# patient# at# the# time#of# the# appointment#was# calculated# using#
Microsoft# Excel®.!The#date#of# birth#was# subtracted# from# the#date# the#patient#was#
seen.# For# statistical# purposes# the# patients# were# grouped# into# two# age# groups.#
Patients# who# were# exactly# six# years# or# greater# but# less# than# ten# years# old# were#
grouped# in# the# (6>10# year# old)# age# group.# Patients#who#were# exactly# 10# years# or#
older,#but#less#or#equal#to#14#years#were#grouped#in#the#(10>14#year#old)#age#group.#
• Race:#Patients#were#classified#as#Black#African#(Black),#Coloured,#Indian#or#White#as#
per# the# Census# 2011(South# Africa)# classification.76# Indian# and# Coloured# patients#
were#grouped#together#in#a#group#called#‘Other’#since#the#number#of#these#patients#
was#negligible.#
• Diagnostic# category:# If# two# diagnoses# on# Axis# I# were# from# the# same# diagnostic#
group,#they#were#counted#as#one#(i.e.#were#not#double#counted;#if#a#patient#suffered#
from# generalised# anxiety# disorder# and# separation# anxiety# disorder,# this# was# only#
counted#as#one#anxiety#disorder).#Diagnoses#were#collected#individually#according#to#










• The# frequencies# of# the# categorical# demographic# data,# clinical# data# and# treatment#
data#were#noted.#
• The#mean#and#standard#deviation#was#calculated#for#the#age#variable.#
• Data# from# the# demographic,# diagnostic# and# psychotropic# categories# were#
investigated# quantitatively# using# the# chi>squared# test.# A# P>value# of# P<# 0.05# was#
considered#significant.##






consent# form# for# the# use# of# their# clinical# data.# Data# was# collected# on# site,# from# an#
office#at#TOCC.#The#primary# researcher#alone#had#access# to# the#patient#names#and#a#
collating# number# was# allocated# to# each# file# number..# This# research# protocol# was#














































A# total# of# 222# psychotropics#were# prescribed# for# the# 205# patients.# Psychostimulants#
were# prescribed# in# over# three>quarters# of# the# population.# (Table# 4.2)# Approximately#
one# quarter# of# patients# was# on# antidepressants.# Psychostimulants# were# more#
commonly#prescribed#to#males,#Black#patients#and#patients#between#the#ages#of#six#and#
ten.# Conversely,# antidepressants#were#most# commonly# prescribed# in#White# patients,#








## Psychostimulant# Antidepressant# Antipsychotic#





# # # #
#
Male# 117#(57.1)# 31#(15.1)# 6#(2.9)#
#
Female# 44#(21.5)# 20#(9.8)# 4#(2.0)#
Age#
# # # #
#
6>10#years# 110#(53.7)# 22#(10.7)# 5#(2.4)#
#
10>14#
years# 51#(24.9)# 29#(14.1)# 6#(2.9)#
Race#
# # # #
#
Black## 94#(45.9)# 22#(10.7)# 6#(2.9)#
#
White# 61#(29.8)# 30#(14.6)# 5#(2.4)#
#
Other# 6#(2.9)# 1#(0.5)# 0#(0)#
!
4.2.2! Statistical! correlations! between! psychotropic! prescription! and!
demographic!variables:!!!
The#following#section#analyses#the#relationships#between#the#psychotropic#prescribed#








The#chi# squared# test#was#performed#to#examine# the#correlation#between#gender#and#





































# The# chi# square# test# showed# significant# association# between# the# age# group# of# the#
patient#and#the#psychotropic#prescribed.#(X2#(2,#N#=#222)#=#12.15#P#=#0.003)#(Figure#4.3)#
















































was# found# between# race# and# antidepressant# prescriptions.# White# patients# were#
statistically#more#likely#to#receive#a#prescription#of#an#antidepressant.#(P#value#=#0.013).#
Only# Black# and# White# patients# are# portrayed# on# this# frequency# diagram# since# the#
numbers# in# the# “Other”# group# were# small# and# would# not# be# accurately# displayed,#










































































the# sample.# The# remaining# diagnostic# categories#were# found# in# less# than# 11%#of# the#
population.#
4.3.2!Diagnostic!profile!compared!to!demographic!variables:!!
Over# 80%# of# the# sample# was# diagnosed# with# ADHD;# the# majority# were# Black# males#
between#the#ages#of#six#and#ten#years#old#(Table#4.4).#The#next#big#category#was#anxiety#




























81# 24.9# 12.2# 8.8# 9.3# 5.4# 5.4#
Age# first#
seen:*#
# # # # # # # #6#>#10#years# 55.6*# 14.6# 3.4*# 5.4# 1.5*# 3.9# 2.4#
10>#14years### 25.4*# 10.2# 8.8*# 3.4# 7.8*# 1.5# 2.9#
#Gender:#
# # # # # # # #Female# 22.4# 10.2# 1.5# 2.4# 2.4# 0.5# 1.5#
Male# 58.5# 14.6# 10.7# 6.3# 6.8# 4.9# 3.9#
Race:#
# # # # # # # #White# 31.2# 15.1*# 4.9# 1.5# 3.4# 2# 3.9#














elimination# disorder,# attachment# disorder,# psychotic# disorder,# pervasive#







group#of# the#patient#and# the#diagnostic# category.# # (X2# (6,#N#=#309)#=#30.72#P#<#0.00)#
(Table#4.4)#Further#analysis#revealed#that#six#to#ten#year#olds#are#more#likely#than#ten#to#
fourteen#year#olds#to#be#diagnosed#with#ADHD#(Fishers#exact#test#P#=#0.00).#Conversely,#
ten# to# fourteen# year# olds# are# statistically# more# likely# to# be# diagnosed# with# a#mood#
disorder#and/or#a#disruptive#disorder.!!
!!!!!!!!!Race:!




















in# 15# patients# who# were# diagnosed# with# ADHD.# (9.03%,# n# =# 15/166)# The# most#






















































Mood8disorder 6 1 7
Disruptive8disorder 1 3 4
Selective8mutism 1 1
Psychotic8disorder 1 1
ADHD,8anxiety8disorder 14 4 5 1 2 26
ADHD,learning8disorder 15 15
ADHD,disruptive8disorder 10 1 1 12
























There# were# 51# patients# diagnosed# with# an# anxiety# disorder.# Anxiety# disorders# are#
commonly# diagnosed# with# other# disorders.# (76.5%# comorbid# diagnoses,# n=39/51)#
(Table# 4.5)# The# most# common# comorbid# diagnosis# with# anxiety# disorders# is# ADHD#
(anxiety# and# ADHD# diagnosis# =# 51%# n# =# 26/51),# followed# by# anxiety# disorder#with# a#
mood#disorder#(anxiety#and#mood#diagnosis,#13.7%,#n=7/51).!Monotherapy#made#up#of#
either# antidepressants# or# psychostimulants# occurred# in# 40# patients# diagnosed# with#
anxiety#disorders.#Twenty>five#of#these#patients#were#on#antidepressants#only.#(49%#(n#
=# 25/51))# Of# the# 26# patients# who# had# anxiety# disorders# and# ADHD,# fifteen#were# on#
psychostimulants# only# (29.4%# n# =15/51).# Only# 34# of# the# 51# children# with# anxiety#
disorders# were# started# on# an# SSRI# (67%).# Concomitant# prescribing# in# patients# with#
anxiety#disorders#only#occurred#in#10#patients.#(19.6#%#n#=#10#/#51)##The#most#common#
combination# of#medication#was# an# antidepressant# and# a# psychostimulant# (See# Table#
4.5).!!
!!!!!!!!!Mood!disorders:!











# Antipsychotics# were# prescribed# in# ten# patients# for# a# variety# of# disorders,# disruptive#
disorder# ±# ADHD# (n# =# 5),# mood# disorder# (n# =# 1),# psychotic# disorder# (n# =# 1)# and# an#





Concomitant# prescribing# occurred# in# 16# patients# (Table# 4.6).# The# majority# of# these#
patients# received# a# combination# of# a# stimulant# and# a# SSRI# for# comorbid# ADHD# and#




























Concomitant# prescribing# occurred# in# 16# patients.# The# majority# of# these# patients#



















Antidepressants:# # # # 51#
SSRI# Fluoxetine# 5# 1# 6#
# Citalopram# 41# 0# 41#








# Atomoxetine# 0# 3# 3#
# # # # #
Antipsychotics:# # # # 10#
  Risperidone## 10# 0# 10#
!
The#majority#of#antidepressants#prescribed#were#off>label.#All#Imipramine#prescriptions#(n=4)#
were# for# a# FDA>approved# condition,# enuresis.# (See#Table#1.1)#Only#one# case#of# # fluoxetine#
prescribing# for#major# depressive# disorder#was# FDA>approved.# The# remaining# 47# fluoxetine#
prescriptions# and# all# citalopram# prescriptions# were# off>label.# Conditions# treated# included#
major#depressive#disorder,#generalised#anxiety#disorder,#adjustment#disorder#and#dysthymic#
disorder.#Risperidone#was#the#only#antipsychotic#prescribed#in#the#sample.#All#prescriptions#










psychostimulants,# antidepressants# and# antipsychotics.# Psychostimulants# were# most#
frequently# prescribed,# followed# by# antidepressants# and# antipsychotics.# Concomitant#




to# females.# This# is# in# keeping# with# the#male# predominance# of# prescriptions# found# in#
previous#research.1#The#age#range#of#the#sample#should#be#interpreted#cautiously,#since#
the#sample#only#looked#at#six#to#fourteen#year#olds.#The#racial#distribution#of#patients#at#
TOCC#does#not# reflect# the#demographic#profile#of# the#South#African#population#where#



















# ADHD#was#most# likely# to# be#diagnosed,# and#psychostimulants#were# significantly#more#





the# highest# number# of# psychostimulant# prescriptions,# whereas# other# research# shows#
that# psychostimulants# are# prescribed# more# in# ten# to# fourteen# year# old# group.9,15# In#





Mood# disorders# were# more# commonly# found# in# the# 10# to# 14# year# old# group,# and#
correspondingly# antidepressants#were#more# likely# to# be# prescribed# in# this# age# group.#
This# is# in# line#with#previous# studies,# and# reflects# the#positive# correlation#between# the#
increase#in#the#rates#of#the#diagnosis#of#mood#disorders#with#increasing#age.25##
# Mood# disorders# commonly# start# in# adolescence,# due# to# a# combination# of# genetic,#
environmental#and#hormonal#factors.#40,77#Stress#is#a#known#predisposing#factor#for#the#






in# the# development# of# a# mood# disorder.11,77# Studies# looking# at# pubertal# status# have#
shown# that# the#onset#of# puberty# is# associated#with#depression.78#Oestrogen#has#been#
linked#to#depression,#and#is#thought#to#account#for#the#differences#in#rates#of#depression#








age# range#and# the# small# sample# size# that#may#have# limited# the#validity#of# the# results.#
Depression#is#more#commonly#found#in#adolescents#compared#to#younger#children,#and#
the# cut>off# of# 14# years# old# in# this# study#may# have# impacted# the# finding# of# no# gender#
differences#in#psychotropic#prescriptions.##
5.3.3!Race:!
# Consistent# with# international# research,# there# was# racial# disparity# in# prescribing#
practices.42,43# Antidepressants# were#more# likely# to# be# prescribed# in#White# patients.# A#
significant#amount#of#literature#looks#at#racial#differences#in#the#diagnosis#of#psychiatric#
disorders# and# antidepressant# prescribing.#Whaley# et# al79# suggests# that# there# are# two#
hypothesis#as#reasons#for#the#discrepancies.#The#first#is#“clinician#bias”,#where#although#

















results.# Looking# specifically# at# ADHD,# comorbid# diagnoses# and# psychostimulants,# certain#
trends# are# observed.# Prescriptions# of# psychostimulants# occurred# in# the# vast# majority# of#
patients#with# ADHD# and# only# 0.03%# of# patients#with# a# diagnosis# of# ADHD# did# not# have# a#
prescription# for# a# psychostimulant.# In# keeping# with# literature,# ADHD# is# most# likely# to# be#
diagnosed# in# isolation;# followed# by# comorbid# diagnoses# of# ADHD# and# either# an# anxiety#
disorder,#ADHD#and#a#learning#disorder#and#ADHD#and#a#disruptive#disorder.48## ##
5.4.2!!!Antidepressants:!










practitioners,# paediatricians# and# psychiatrists,# whereas# this# study# was# limited# to# child#
psychiatrists#and#psychiatric#registrars.#Perhaps,#child#psychiatrists/psychiatric#registrars,#by#
virtue#of#their#additional#training#are#more#comfortable#in#prescribing#SSRI’s#for#children.#
# This# study# revealed# that,# although# SSRIS# are# the# first# line# pharmacological# treatment# for#






psychosocial# measures# e.g.# Low# intensity# treatment# (books,# CDs),# CBT# or# skills># based#
treatment.25,80# Additionally# when# anxiety# disorders# are# comorbid# with# ADHD,# ACAPAP#
guidelines# recommend# treating# ADHD# first.80# Fifteen# of# our# study# patients#with# comorbid#
ADHD# and# anxiety# disorders# were# prescribed# only# psychostimulants# following# these#
guidelines.##Only#six#patients#with#comorbid#diagnoses#(ADHD#and#mood/anxiety#disorders)#
received# psychostimulants# and# antidepressants.# It# would# have# been# useful# to# note# the#
severity# of# the# anxiety# disorder# when# collecting# the# data,# so# that# it# could# have# been#
determined#why#the#patients#were#started#on#two#agents#at#the#first#visit.##
# With# regards# to#mood#disorders,# the# large#majority#of#patients# received#SSRI’s#on# the# first#
visit.# Once# again# it# would# have# been# useful# to# determine# the# severity# of# the# illness,# to#
determine# if# immediate# prescribing# was# indicated.# ACAPAP# and# NICE# guidelines# both#
recommend#where#possible# that#psychosocial# interventions#and#or# ‘wait# full#watching’#are#





shortage# of# child# and# adolescent#mental# health# services# in# South#Africa,# and# this# perhaps#
results# in# patients# receiving# pharmacological# treatment# instead# of# more# intensive#
psychosocial# interventions.82# Reasons# for# not# following# these# guidelines# need# to# be#
investigated#further.##
5.4.3!Antipsychotics:!
# Prescriptions# of# antipsychotics# were# mainly# for# off>label# indications.# # A# diagnosis# of#
disruptive# disorder# was# most# likely# associated# with# antipsychotic# prescription.# This# is# in#
keeping# with# international# trends.46# (See# Table# 2.1# and# 2.2).# Only# eleven# patients# in# the#
sample#(5%)#started#on#antipsychotics#on#their#first#encounter#with#the#doctor#–#all#atypical#
antipsychotics.# This# is# considerably# less# than# other# aforementioned# research# e.g.# Raman#
found#a#15%#rate#of#antipsychotic#prescription#at#the#child#psychiatric#clinic#in#RMH.17##
# This# relatively# small#number# is# a#positive# finding,#especially# considering# the# side#effects#of#
these#medications# and# the# relative# paucity# of# data# in# this# area.# However,# it# is# difficult# to#
compare# this# result#directly#with#other# studies# since# the#majority#of#other# studies# showed#
higher# percentages# of# antipsychotic# prescription,# and# looked# at# overall# prescribing# during#
multiple# visits,# whereas# this# study# looked# at# initial# prescription# at# the# time# of# the# first#
presentation#to#TOCC.#
# It# would# be# useful# to# follow# this# group# of# children,# to# determine# how# many# eventually#
received# antipsychotics# for# behavioural# disturbances.# As# shown# by# Lund# et# al’s# research81#
there#are# few#psychosocial# interventions#available# to# treat# these# children,# so# it# is#possible#








sample# receiving# only# one# psychotropic# (Table# 4.6).# This# is# much# lower# than# previously#
mentioned# research.70,72,73,74# However# it# must# be# remembered# that# this# research# is# only#




# Retrospective# studies# are# known# to# have# limitations# such# as# reliability,# validity,# with# the#
accessibility# of# data# being# a#main# concern.# This# study# focuses# purely# on# notes#written# by#
doctors#in#the#files,#and#the#accuracy#of#these#notes#and#diagnoses#cannot#be#verified.#Only#
one#doctor#systematically#reviewed#every#file#and#collected#data,#to#decrease#collection#bias.#
There#were# ten#missing# files,#which#may#have#otherwise#contributed# to# the#data#collected#
and#findings.#
# It#should#be#noted#that#these#results#were#based#on#only#two#years#of#data,#so#it#is#difficult#to#
comment# on# changes# in# prescription# trends# over# the# years.# Furthermore,# comparisons#
cannot# be# made# with# patients# not# receiving# medications.# The# findings# of# this# study# are#
restricted# to# initial# prescription#patterns,# so# the#overall# prescribing# patterns# over#multiple#
visits#at#TOCC#are#not#known.#This#study#did#not#look#at#dosages,#which#would#have#been#an#
additional#variable#to#compare.#








population# makes# it# difficult# to# make# accurate# comparisons# to# other# studies.# Another#
limitation#is#that#this#study#did#not#look#at#additional#socio>economic#data#in#these#patients,#
which#would#have#been#helpful# in#picking#up# trends# in# special#populations#e.g.# children# in##
instutions#or#in#foster#care.#This#would#have#been#useful#since#there#is#considerable#research#
on#psychotropic#use#in#these#populations.52,#53#
# Another# limitation# of# the# study# was# the# manner# in# which# diagnostic# categories# were#






local#knowledge# in#South#Africa.17,21,34,50#Research#that# is#completed# locally#could#hopefully#
help#validate#allocation#of#resources#and#need#for#more#training#in#this#mental#health#field.81#
This# research# has# also# pointed# out# some# significant# findings# at# TOCC,# of# which# the#
prescribing#doctors#may#not#be#aware.#These#include#the#findings#with#regards#to#race#and#
psychotropic# prescribing# differences,# as# well# as# the# high# prescription# rates# of#










# In# South# Africa,# there# are# no# published# guidelines# for# treatment# of# children# with#
antipsychotics# or# antidepressants,# and# the# use# of# these# medications# is# based# on# the#
International#Association#for#Child#and#Adolescent#Psychiatry#and#Allied#Professions#(ICAPAP)#
guidelines# or# NICE# guidelines.8,9,25,26,35,48,49,55,56,81# Psychostimulants# were# frequently#
prescribed# for# the# treatment# of# ADHD# according# to# local# guidelines.13# SSRI’s# are# used#
predominantly# for# treatment# of# mood# and# anxiety# disorders,# whilst# TCAs# were# only#
prescribed#for#elimination#disorders.#Due#to#the#limited#registered#uses#of#antipsychotics,#the#




features# of# six# to# fourteen# year# old# children# attending# TOCC# have# been# described.# It# has#
shown# that# prescription# patterns# of# psychotropics# at# TOCC# mostly# follow# international#
demographic# trends#and#clinical#guidelines.#Hopefully,# this# study#adds# to# the#small#pool#of#
research# in# South# Africa# looking# at# prescribing# patterns# of# psychotropics# in# children.# It# is#
hoped#that#this#study#at#TOCC#may#stimulate#more#in>depth#research#at#South#African#child#
psychiatry# outpatient# units.# Future# research# should# look# at# expanding# the# sample# size# by#
including#a#wider#age#range,#as#this#would#greatly# improve#the#usefulness#of#the#data,#and#
give#a#more#accurate#picture#of#the#prescribing#practices#with#regard#to#conditions#seen#at#
Child#Outpatient#Psychiatric# Services#at#Tara#H#Moross#Hospital.# The#patients# in# this# study#









































































































































































































































































































































































T r e a t m e n t !  C a t e g or y S p e c i f i e d !  d i a g n o s i s 
S e l e c t i v e !  s e r o t o n i n !  r e W u p t ak e !  i n h i b i t o r C i t a l o p r a m 
F l u o x e t i n e 
T r i c y c l i c !  a n t i d e p r e s s a n t I m i p r a m i n e 
P s y c h o s t i m u l a n t M e t h y l p h e n i d a t e !  I R 
M e t h y l p h e n i d a t e !  L A 
M e t h y l p h e n i d a t e !  E x t e n d e d W !  R e l e a s e !  T a b l e t s
A t o m o x e t i n e * 
A n t i W p s y c h o t i c R i s p e r i d o n e 
* A t o m o x e t i n e W !  a l t h o u g h !  t h i s !  i s !  n o t !  a !  p s y c h o s t i m u l a n t !  i t !  w a s !  i n c l u d e d !  i n !  t h i s !  g r o u p !  s i n c e !  i t !  w a s !  p r e s c r i b e d !  f o r !  A D H D 
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! Appendix!6:!
!!
Ethics!clearance:!
! !
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Appendix!7:!
!
Flow!chart!showing!patients!who!were!diagnosed!with!Attention!deficit!hyperactivity!disorder,!the!
medication!they!were!treated!with!and!diagnositic!coWmorbidities: 
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Appendix!8:!
!
Flow!chart!showing!patients!who!were!diagnosed!with!Anxiety!disorders,!the!medication!they!were!
treated!with!and!diagnostic!coWmorbidities:!
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Appendix!9:!
 
Flow!chart!showing!patients!who!were!diagnosed!with!Disruptive!disorder,!the!medication!they!were!
treated!with!and!diagnostic!coWmorbidities!
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